Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
KGEN001
- Development stage
- Preclinical
- Lead developer
- KiraGen Bio
- Modality
- Allogeneic CAR-T → CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies, CAR-NK Cells → Other Engineered Cells → Adoptive Cell Transfer → Cell Therapies, Allogeneic iPSCs → iPSCs → Pluripotent Stem Cells → Stem Cell Therapies → Cell Therapies
01
Overview
KGEN001 is a pre-clinical allogeneic cell therapy being developed by KiraGen Bio for the treatment of glioblastoma. The therapy is designed to target two specific markers: stromal interaction molecule 2 (STIM2) and glial cell line-derived neurotrophic factor receptor alpha 1 (GFR1 or GFRA1). STIM2 is a calcium sensor that regulates endoplasmic reticulum calcium stores and signaling, which can influence tumor cell proliferation and survival. GFR1 is a receptor component for the glial cell line-derived neurotrophic factor (GDNF) family, which plays a role in the growth and migration of glial cells. By utilizing an allogeneic (off-the-shelf) platform, KGEN001 aims to provide a more accessible and scalable cellular immunotherapy for patients with aggressive brain tumors compared to patient-specific autologous treatments.
- Other names
- KGEN-001KGEN001KGEN 001
02
Targets
GFRA1 (Glial cell line-derived neurotrophic factor family receptor alpha 1)STIM2 (Stromal interaction molecule 2)
Beyond the preview
Go deeper on KGEN001.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on KGEN001.